BioNTech SE (VIE:BNTX)

Austria flag Austria · Delayed Price · Currency is EUR
83.60
+0.60 (0.72%)
At close: Dec 3, 2025
-25.82%
Market Cap19.79B
Revenue (ttm)3.15B
Net Income (ttm)-571.60M
Shares Outn/a
EPS (ttm)-2.38
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume257
Open83.40
Previous Close83.00
Day's Range83.00 - 83.60
52-Week Range72.40 - 124.50
Betan/a
RSI38.97
Earnings DateMar 10, 2026

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 6,772
Stock Exchange Vienna Stock Exchange
Ticker Symbol BNTX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.